Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.05 and traded as low as $7.45. Aurinia Pharmaceuticals shares last traded at $7.59, with a volume of 1,404,253 shares traded.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.
Check Out Our Latest Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Trading Up 5.9%
The firm has a 50-day moving average of $8.04 and a 200-day moving average of $8.08. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93. The firm has a market capitalization of $1.20 billion, a P/E ratio of 31.84 and a beta of 1.16.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The firm had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. On average, equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Large investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $27,000. Tower Research Capital LLC TRC grew its position in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $31,000. Finally, GAMMA Investing LLC lifted its stake in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the period. 36.83% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
